Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs [Yahoo! Finance]
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension [Yahoo! Finance]
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]